Gamida Cell Stock Fundamentals
| GMDADelisted Stock | USD 1.40 0.09 6.04% |
Gamida Cell fundamentals help investors to digest information that contributes to Gamida Cell's financial success or failures. It also enables traders to predict the movement of Gamida Stock. The fundamental analysis module provides a way to measure Gamida Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gamida Cell stock.
Gamida |
Gamida Cell Company Operating Margin Analysis
Gamida Cell's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Gamida Cell Operating Margin | (26.80) % |
Most of Gamida Cell's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gamida Cell is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Gamida Cell has an Operating Margin of -26.8024%. This is 23.6% lower than that of the Biotechnology sector and 76.08% lower than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Gamida Cell Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gamida Cell's current stock value. Our valuation model uses many indicators to compare Gamida Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gamida Cell competition to find correlations between indicators driving Gamida Cell's intrinsic value. More Info.Gamida Cell is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gamida Cell's earnings, one of the primary drivers of an investment's value.Gamida Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gamida Cell's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gamida Cell could also be used in its relative valuation, which is a method of valuing Gamida Cell by comparing valuation metrics of similar companies.Gamida Cell is currently under evaluation in operating margin category among its peers.
Gamida Fundamentals
| Return On Equity | -11.04 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (26.80) % | |||
| Current Valuation | 70.28 M | |||
| Shares Outstanding | 132.64 M | |||
| Shares Owned By Insiders | 11.57 % | |||
| Shares Owned By Institutions | 26.48 % | |||
| Number Of Shares Shorted | 10.96 M | |||
| Price To Earning | (3.97) X | |||
| Price To Book | 117.40 X | |||
| Price To Sales | 6.44 X | |||
| Revenue | 1.78 M | |||
| EBITDA | (70.62 M) | |||
| Net Income | (63 M) | |||
| Cash And Equivalents | 55.06 M | |||
| Cash Per Share | 0.92 X | |||
| Total Debt | 82.94 M | |||
| Current Ratio | 2.57 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (79.12 M) | |||
| Short Ratio | 3.51 X | |||
| Earnings Per Share | (0.82) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 143 | |||
| Beta | 1.03 | |||
| Market Capitalization | 4.34 M | |||
| Total Asset | 102.19 M | |||
| Retained Earnings | (479.83 M) | |||
| Working Capital | 29.34 M | |||
| Current Asset | 56.03 M | |||
| Current Liabilities | 9.55 M | |||
| Net Asset | 102.19 M |
About Gamida Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gamida Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gamida Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gamida Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company was founded in 1998 and is headquartered in Jerusalem, Israel. Gamida Cell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 166 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Gamida Stock
If you are still planning to invest in Gamida Cell check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gamida Cell's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |